Hyloris Pharmaceuticals SaEURONEXT: HYL

Consolidated 2026 Half-Year Report: Hyloris Delivers 56% Revenue Growth and Its Lowest Half-Year Net Loss Since IPO, Advances Its Mavericks, Core Drivers and Promising Seeds

Sep 28, 2026 at 8:24 AM UTC · Issued by Hyloris Pharmaceuticals SA

28 Sep 2026 10:15 CEST

Issuer

HYLORIS PHARMACEUTICALS SA

hyloris-half-year-report-26.pdf

Source

HYLORIS

Provider

Euronext

Company Name

HYLORIS

ISIN

BE0974363955

Symbol

HYL

Market

Euronext

Company press releases subscription ×

To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.

Cancel

Earlier from Hyloris Pharmaceuticals Sa